Cognition Therapeutics Says 'In The SHINE Study, CT1812 Did Not Achieve Statistical Significance On The First Of The Ordered Secondary Efficacy Endpoints In The Pooled 100mg And 300mg Dose Group Compared To Placebo'
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics announced that in the SHINE study, their drug CT1812 did not achieve statistical significance on the first of the ordered secondary efficacy endpoints in the pooled 100mg and 300mg dose group compared to placebo.
July 29, 2024 | 11:58 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cognition Therapeutics' SHINE study results indicate that their drug CT1812 did not achieve statistical significance on the first secondary efficacy endpoint in the pooled 100mg and 300mg dose group compared to placebo.
The failure to achieve statistical significance on a key efficacy endpoint in a clinical study is likely to negatively impact investor sentiment and the stock price of Cognition Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100